Skip to content
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Country/Region
  • No block ID is set

  • Clinic Portal
    • +0034963905310
  • Request Information
  • +34 96 390 53 10
  • Part of brands: |
InternationalInternational
  • Country/Region
  • Part of brands: |
  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
Genomics Precision Diagnostic > Immunology Precision Panel > Chronic Granulomatous Disease Precision Panel

Chronic Granulomatous Disease Precision Panel

Chronic Granulomatous Disease (CGD) is a genetically heterogeneous condition featuring recurrent, life-threatening bacterial and fungal infections as well as granuloma formation. CGD is caused by defects in the oxidative mechanisms found in phagocytes that are responsible for the destruction of certain microbes.
Overview
Indication
Clinical Utility
Genes & Diseases
Methodology
References

Overview

  • Chronic Granulomatous Disease (CGD) is a genetically heterogeneous condition featuring recurrent, life-threatening bacterial and fungal infections as well as granuloma formation. CGD is caused by defects in the oxidative mechanisms found in phagocytes that are responsible for the destruction of certain microbes. Thus, these genetic defects result in a primary immunodeficiency caused by the inability of phagocytes to destroy foreign microbes. The characteristic infections of patients with CGD are those caused by catalase positive microorganism in the lung, skin, lymph nodes and liver. Symptoms typically appear during the first year of life in the form of infections, dermatitis, gastrointestinal complications and failure to thrive. This disease primarily affects males, and the mode of inheritance is X-linked.  

  • The Igenomix Chronic Granulomatous Disease Precision Panel can be used for an accurate and directed diagnosis as well as differential diagnosis of recurrent infections ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved. 

     

Indication

  • The Igenomix Chronic Granulomatous Disease Precision Panel is used for patients with a clinical diagnosis or suspicion with or without the following symptoms: 
    • Recurrent bacterial infections 
    • Recurrent fungal infections 
    • Growth failure 
    • Abnormal wound healing 
    • Diarrhea 
    • Granulomatous dermatitis 
    • Hepatomegaly 
    • Splenomegaly
    • Lymphadenitis 

Clinical Utility

The clinical utility of this panel is: 

  • The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient. 
  • Early initiation of antimicrobial prophylaxis with antibacterial, antifungal and immunomodulators, rapid recognition and treatment of infections as well as aggressive management of infectious complications. In case of multidrug refractoriness, life-threatening infections, hematopoietic stem cell transplantation (HSCT) represents a valid curative option.  
  • Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance.  
  • Improvement of delineation of genotype-phenotype correlation.  

Genes & Diseases

Methodology

References

See scientific referrals

Winkelstein, J., Marino, M., Johnston, R., Boyle, J., Curnutte, J., & Gallin, J. et al. (2000). Chronic Granulomatous Disease: Report on a National Registry of 368 Patients. Medicine, 79(3), 155-169. doi: 10.1097/00005792-200005000-00003 

van den Berg, J., van Koppen, E., Åhlin, A., Belohradsky, B., Bernatowska, E., & Corbeel, L. et al. (2009). Chronic Granulomatous Disease: The European Experience. Plos ONE, 4(4), e5234. doi: 10.1371/journal.pone.0005234 

Roos, D., & de Boer, M. (2014). Molecular diagnosis of chronic granulomatous disease. Clinical & Experimental Immunology, 175(2), 139-149. doi: 10.1111/cei.12202 

Segal, B., Romani, L., & Puccetti, P. (2009). Chronic granulomatous disease. Cellular And Molecular Life Sciences, 66(4), 553-558. doi: 10.1007/s00018-009-8506-y 

Arnold, D., & Heimall, J. (2017). A Review of Chronic Granulomatous Disease. Advances In Therapy, 34(12), 2543-2557. doi: 10.1007/s12325-017-0636-2 

Agarwal, S. (2015). Chronic Granulomatous Disease. Journal Of Clinical And Diagnostic Research. doi: 10.7860/jcdr/2015/12139.5945 

Roos D. (2016). Chronic granulomatous disease. British medical bulletin, 118(1), 50–63. https://doi.org/10.1093/bmb/ldw009 

Rider, N. L., Jameson, M. B., & Creech, C. B. (2018). Chronic Granulomatous Disease: Epidemiology, Pathophysiology, and Genetic Basis of Disease. Journal of the Pediatric Infectious Diseases Society, 7(suppl_1), S2–S5. https://doi.org/10.1093/jpids/piy008 

descargar

Detail description

Download

Request Information

WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

OUR SERVICES

Genetic testing solutions
For patients
How to send a sample?
User manual

ABOUT US

About Igenomix
Contact
Quality
Complaints
Work with us
Terms and conditions

FOLLOW IGENOMIX

  + 96 390 53 10
  Write us
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
Country/Region

[2024] © Igenomix Privacy Page Quality policy Legal note Cookies policy

Request Information


  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
  • Country/Region
  • +34 96 390 53 10
  • Clinic Portal
  • Request Information